Mind Medicine (MindMed) Inc. Completes $34.5 Million Bought Deal Prospectus Offering

December 11, 2020

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness, completed a bought deal prospectus offering of 18,170,000 units for aggregate gross proceeds of $34,523,000. The offering was conducted by Canaccord Genuity Corp., as lead underwriter, and Eight Capital.

Wildeboer Dellelce LLP acted for MindMed in connection with the offering with a team comprised of Perry Dellelce, Peter Volk, Rebecca Cochrane and Katie Drury (corporate/securities) and Katy Pitch and Marija Tasevska (tax).